Adapt Pharma Limited has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Narcan (naloxone) Nasal Spray, an investigational drug intended to treat opioid overdose.

Narcan Nasal Spray has been granted Fast Track Designation by the FDA. Within 60 days of the submission date, the FDA will determine whether it will accept the application for review as filed. Narcan Nasal Spray was developed in collaboration with the National Institutes on Drug Abuse (NIDA).

For more details, go to: http://www.businesswire.com/news/home/20150727005235/en/Adapt-Pharma-Submits-NDA-FDA-Narcan®-naloxone#.VbbvXXjC1Vs